Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAIC + surufatinib + tislelizumab
- Development stage
- Unknown
- Lead developer
- Union Hospital of Huazhong University of Science and Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Hepatic Arterial Infusion, Oral, Intravenous
01
Overview
HAIC + surufatinib + tislelizumab is a combination treatment regimen being investigated for the first-line treatment of unresectable or metastatic biliary tract cancer. The regimen consists of Hepatic Arterial Infusion Chemotherapy (HAIC) using the FOLFOX protocol (oxaliplatin, fluorouracil, and leucovorin), which delivers high concentrations of chemotherapy directly to the liver to maximize local control. This is combined with surufatinib, an oral small-molecule tyrosine kinase inhibitor that targets VEGFR1/2/3, FGFR1, and CSF-1R to inhibit angiogenesis and modulate the tumor microenvironment, and tislelizumab, a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting the PD-1 receptor. This triple-modality approach is designed to synergize local regional therapy with systemic anti-angiogenic and immune-mediated anti-tumor activity.
- Other names
- HAIC + FOLFOX + surufatinib + tislelizumabCombination Therapy of HAIC, Surufatinib and Tislelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on HAIC + surufatinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAIC + surufatinib + tislelizumab.